Aprea Therapeutics Stock Forecast, Price & News

+0.03 (+0.71 %)
(As of 07/27/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume784,992 shs
Average Volume2.33 million shs
Market Capitalization$90.26 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive APRE News and Ratings via Email

Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Aprea Therapeutics logo

About Aprea Therapeutics

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.93 out of 5 stars

Medical Sector

711th out of 2,218 stocks

Pharmaceutical Preparations Industry

340th out of 869 stocks

Analyst Opinion: 3.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Aprea Therapeutics (NASDAQ:APRE) Frequently Asked Questions

Is Aprea Therapeutics a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aprea Therapeutics in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Aprea Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in APRE, but not buy additional shares or sell existing shares.
View analyst ratings for Aprea Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Aprea Therapeutics?

Wall Street analysts have given Aprea Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aprea Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Aprea Therapeutics?

Aprea Therapeutics saw a drop in short interest in the month of July. As of July 15th, there was short interest totaling 1,090,000 shares, a drop of 42.3% from the June 30th total of 1,890,000 shares. Based on an average daily trading volume, of 3,330,000 shares, the days-to-cover ratio is currently 0.3 days. Currently, 7.4% of the shares of the company are sold short.
View Aprea Therapeutics' Short Interest

When is Aprea Therapeutics' next earnings date?

Aprea Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Aprea Therapeutics

How were Aprea Therapeutics' earnings last quarter?

Aprea Therapeutics, Inc. (NASDAQ:APRE) released its earnings results on Thursday, May, 6th. The company reported ($0.46) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.49) by $0.03.
View Aprea Therapeutics' earnings history

How has Aprea Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Aprea Therapeutics' stock was trading at $32.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, APRE shares have decreased by 86.9% and is now trading at $4.26.
View which stocks have been most impacted by COVID-19

What price target have analysts set for APRE?

6 equities research analysts have issued 12 month price targets for Aprea Therapeutics' shares. Their forecasts range from $6.00 to $37.00. On average, they expect Aprea Therapeutics' stock price to reach $14.25 in the next year. This suggests a possible upside of 234.5% from the stock's current price.
View analysts' price targets for Aprea Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Aprea Therapeutics' key executives?

Aprea Therapeutics' management team includes the following people:
  • Mr. Christian S. Schade, Pres, CEO & Chairman (Age 60, Pay $798.25k)
  • Mr. Scott M. Coiante, Sr. VP, Company Sec. & CFO (Age 54, Pay $512.45k)
  • Dr. Eyal C. Attar M.D., Sr. VP & Chief Medical Officer (Age 50, Pay $630.36k)
  • Dr. Lars B. Abrahmsen, Sr. VP & Chief Scientific Officer (Age 64)
  • Dr. Gregory A. Korbel Ph.D., Sr. VP & Chief Bus. Officer (Age 45)

Who are some of Aprea Therapeutics' key competitors?

What other stocks do shareholders of Aprea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aprea Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Biogen (BIIB), Axon Enterprise (AAXN), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Alkermes (ALKS), Allogene Therapeutics (ALLO), Alnylam Pharmaceuticals (ALNY) and Amgen (AMGN).

When did Aprea Therapeutics IPO?

(APRE) raised $52 million in an initial public offering on Thursday, October 3rd 2019. The company issued 5,000,000 shares at $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as the underwriters for the IPO.

What is Aprea Therapeutics' stock symbol?

Aprea Therapeutics trades on the NASDAQ under the ticker symbol "APRE."

How do I buy shares of Aprea Therapeutics?

Shares of APRE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aprea Therapeutics' stock price today?

One share of APRE stock can currently be purchased for approximately $4.26.

How much money does Aprea Therapeutics make?

Aprea Therapeutics has a market capitalization of $90.26 million. The company earns $-53,480,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis.

How many employees does Aprea Therapeutics have?

Aprea Therapeutics employs 11 workers across the globe.

What is Aprea Therapeutics' official website?

The official website for Aprea Therapeutics is

Where are Aprea Therapeutics' headquarters?

Aprea Therapeutics is headquartered at 535 BOYLSTON STREET, BOSTON MA, 02116.

How can I contact Aprea Therapeutics?

Aprea Therapeutics' mailing address is 535 BOYLSTON STREET, BOSTON MA, 02116. The company can be reached via phone at 609-510-4718 or via email at [email protected]

This page was last updated on 7/28/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.